Farrukh T. Awan

Hematology | Oncology

2201 Inwood Rd
Dallas, TX 75235

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 144 publications

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2026

CLO26-086: Pre-Exposure Prophylaxis With Pemivibart in Adults With Hematologic Malignancies: A Single-Center Cohort.

CLO26-086: Pre-Exposure Prophylaxis With Pemivibart in Adults With Hematologic Malignancies: A Single-Center Cohort.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Female sex is associated with superior outcomes in patients treated with CD19-directed CAR T-cell therapy for large B-cell lymphoma.

Female sex is associated with superior outcomes in patients treated with CD19-directed CAR T-cell therapy for large B-cell lymphoma.

Journal: Haematologica

Published: March 31, 2026

CLO26-086: Pre-Exposure Prophylaxis With Pemivibart in Adults With Hematologic Malignancies: A Single-Center Cohort.

CLO26-086: Pre-Exposure Prophylaxis With Pemivibart in Adults With Hematologic Malignancies: A Single-Center Cohort.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma.

Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma.

Journal: Transplantation and cellular therapy

Published: March 20, 2026

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 13, 2026

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.

Journal: Journal of hematology & oncology

Published: March 09, 2026

CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial.

CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial.

Journal: Blood

Published: February 20, 2026

CD19 CAR T Therapy Is Feasible in Patients with Pemphigus Vulgaris Treated Without Lymphodepletion in the RESET-PV Trial.

CD19 CAR T Therapy Is Feasible in Patients with Pemphigus Vulgaris Treated Without Lymphodepletion in the RESET-PV Trial.

Journal: Blood

Published: February 20, 2026

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Journal: Blood advances

Published: February 17, 2026

Showing 1-12 of 144

Last Updated: 09/26/2026